167 results about "Mitochondrial targeting" patented technology

The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.

Disclosed is a near infrared laser-driven mitochondrial targeting fluorescent polymer and a preparation method and application thereof. A nano-scale photosensitizer, which is prepared from a polymer of poly-(2Z, 2'Z)-3,3'-(2, 5-bis(diphenylamino)-1, 4-phenyl) bis(2-(3, 5-bis(trifluoromethyl) phenyl) acrylonitrile-copolymer (N-(2-hydroxypropyl) methacrylamide)-copolymer (2-dimethylamino ethyl methacrylate) and an inorganic upconversion nano-scale particle of ytterbium and thulium codoped sodium yttrium fluoride in aqueous solution; when irradiated by laser of a wavelength of 980 nm, the nano-scale photosensitizer can produce reactive oxygen to effectively kill cells. The invention provides a novel and effective nano-scale photosensitive material for research and application of photodynamic therapy of tumor cells in the future.

The invention discloses a water soluble mitochondrial targeting imaging probe and a preparation method thereof. The structural formula of compounds that form the water soluble mitochondrial targeting imaging probe can be formula (I), (II), (III), (IV), (V), or (VI). The water soluble mitochondrial targeting imaging probe has the characteristics of good water solubility, high resistance to photo-bleaching, high thermal stability, low toxicity, and high sensitivity. Hela, MCF-7, and NIH-3T3 cells are taken as the models to observe the distribution situation of the fluorescent probe in cells through a laser con-focal microscopy technology; the results show that the probe is mainly distributed in mitochondrial, and the targeting property is good. The test results show that the provided probe has the characteristic of strong mitochondrial targeting imaging performance on cancer cells and non-cancer cells; thus an effective means is provided for quantitatively research superoxide radicals in cells in time and space, and thus the pathologic and physiological mechanisms of active oxygen radicals can be researched.

The invention provides an organic AIE photosensitive probe with mitochondrial targeting and a preparation method and application thereof, and belongs to the technical field of antitumor drugs. The organic AIE photosensitive probe with mitochondrial targeting has a structure as shown in the following formula I in the specification. According to the organic AIE photosensitive probe, mitochondrial ROS oxidative stress is triggered, a large amount of calreticulin translocation is induced to be generated, the immunogenicity of tumor cells is effectively improved, and lasting anti-tumor immune response of an organism is triggered. Therefore, the organic AIE photosensitive probe is applied to preparation of drugs for tumor cell immune response or preparation of reagents for triggering the mitochondrial ROS oxidative stress and inducing generation of calreticulin transposition.

The invention discloses a curcumin micelle eye drop. The eye drop comprises curcumin as a main drug, an antiseptic, an isotonic regulator, and also comprises a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol copolymer as a drug adjuvant, and dequalinium chloride as a mitochondrial targeting modifier and a stabilizer, a mass ratio of the curcumin main drug to the polyethylene caprolactam-polyvinyl acetate-polyethylene glycol block copolymer drug adjuvant is 1:12-1:20, and a mass ratio of dequalinium chloride to the polyethylene caprolactam-polyvinyl acetate-polyethylene glycol copolymer drug adjuvant is 1:20-1:40. The administration concentration of the curcumin micelle eye drop prepared in the invention can reach 5mg / ml, and the eye drop has the advantages of small micelle particle size, uniform distribution range, good drug stability, reduction of the administration irritation, improvement of the drug absorption of cornea, reduction of the administration concentration, prolongation of the action time of the drug, reduction of the administration frequency, improvement of the patient compliance, and very good economy.

A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described.

The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.

Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA.

The invention discloses a cross-linkable mitochondrial targeting pegylated phospholipid medicinal material. Please see the structural formula of the cross-linkable mitochondrial targeting pegylated phospholipid medicinal material in the specification, wherein n is equal to 10, 12, 14 and 16. The preparation method includes the steps that fatty acid acyl phosphatidylethanolamine-polyethylene glycol(peg)-maleimide, polypeptide D- (KLAKLAK)2-C5 and organic base serve as raw materials, and the molecular ratio of the polypeptide to the organic base to the fatty acid acyl phosphatidylethanolamine-polyethylene glycol(peg)-maleimide is (1-3): (1-3):1; under protection of nitrogen, the fatty acid acyl phosphatidylethanolamine-polyethylene glycol(peg)-maleimide, the organic base and a first solvent are mixed so that a first solution can be obtained, the polypeptide is dissolves in a second solvent so that a second solution can be obtained, the first solution and the second solution are mixed, and a mixed solution is stirred to react for 12-8 h at the temperature of 20-40 DEG C. Medicine carrying liposome prepared from the medicinal material can further improve the tumor treatment effect, the toxic and side effects are reduced, and long-time preservation is facilitated.